Cargando…

2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy

BACKGROUND: Patients with hematologic malignancies (HM) are at risk of invasive fungal disease (IFD). Identification of those patients at the highest risk for IFD would help optimize prophylactic or preemptive treatment decisions in this population. We previously found that among patients with myelo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bold, Tyler D, Vedula, Rahul S, Cheng, Matthew P, Marty, Francisco M, Lindsley, R Coleman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810134/
http://dx.doi.org/10.1093/ofid/ofz360.2274
_version_ 1783462173657268224
author Bold, Tyler D
Vedula, Rahul S
Cheng, Matthew P
Marty, Francisco M
Lindsley, R Coleman
author_facet Bold, Tyler D
Vedula, Rahul S
Cheng, Matthew P
Marty, Francisco M
Lindsley, R Coleman
author_sort Bold, Tyler D
collection PubMed
description BACKGROUND: Patients with hematologic malignancies (HM) are at risk of invasive fungal disease (IFD). Identification of those patients at the highest risk for IFD would help optimize prophylactic or preemptive treatment decisions in this population. We previously found that among patients with myeloid malignancies who develop invasive aspergillosis, 15% had a mutation in the gene GATA2. Here, we report the incidence of IFD in a cohort of patients with HM related to a pathogenic sequence variant of GATA2. METHODS: We identified 6343 patients cared for at Dana-Farber/Brigham and Women’s Cancer Center between January 2014 and August 2018 who underwent a next-generation sequencing assay of 95 genes recurrently mutated in hematologic malignancy. Those found to have a pathogenic GATA2 sequence variant were selected for retrospective chart review with respect to serious infectious complications including IFD. RESULTS: We identified 54 patients with a pathogenic GATA2 variant. 5 had a germline mutation related to familial GATA2 deficiency. The other 49 had a HM, mostly (41/49) acute myeloid leukemia or myelodysplastic syndrome. The frequency of the variant GATA2 allele in this group ranged from 2.5 to 92.0% of sequencing reads. 14 patients were excluded due to lack of sufficient follow-up, often related to treatment at another institution. Of the remaining 35 patients, 13 (37%) had proven/probable invasive fungal infection (IFI). Fourteen others had syndromes consistent with possible IFD. In total, 16 of these 35 patients (46%) received antifungal therapy for proven, probable or possible IFD. Four of the patients not treated with antifungals were diagnosed with a serious infection including 2 cases of Staphylococcus aureus bacteremia, and one case of disseminated Mycobacterium avium complex. CONCLUSION: We identified a high incidence of IFD among patients with HM related to a pathogenic sequence variant of GATA2. The wide range of variant allele frequency observed raises the possibility that either inherited or acquired GATA2 dysfunction could incur predisposition to infection. These data suggest that personalized genetic diagnostics of patients with HM may be useful for assessment of infectious risk. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810134
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68101342019-10-28 2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy Bold, Tyler D Vedula, Rahul S Cheng, Matthew P Marty, Francisco M Lindsley, R Coleman Open Forum Infect Dis Abstracts BACKGROUND: Patients with hematologic malignancies (HM) are at risk of invasive fungal disease (IFD). Identification of those patients at the highest risk for IFD would help optimize prophylactic or preemptive treatment decisions in this population. We previously found that among patients with myeloid malignancies who develop invasive aspergillosis, 15% had a mutation in the gene GATA2. Here, we report the incidence of IFD in a cohort of patients with HM related to a pathogenic sequence variant of GATA2. METHODS: We identified 6343 patients cared for at Dana-Farber/Brigham and Women’s Cancer Center between January 2014 and August 2018 who underwent a next-generation sequencing assay of 95 genes recurrently mutated in hematologic malignancy. Those found to have a pathogenic GATA2 sequence variant were selected for retrospective chart review with respect to serious infectious complications including IFD. RESULTS: We identified 54 patients with a pathogenic GATA2 variant. 5 had a germline mutation related to familial GATA2 deficiency. The other 49 had a HM, mostly (41/49) acute myeloid leukemia or myelodysplastic syndrome. The frequency of the variant GATA2 allele in this group ranged from 2.5 to 92.0% of sequencing reads. 14 patients were excluded due to lack of sufficient follow-up, often related to treatment at another institution. Of the remaining 35 patients, 13 (37%) had proven/probable invasive fungal infection (IFI). Fourteen others had syndromes consistent with possible IFD. In total, 16 of these 35 patients (46%) received antifungal therapy for proven, probable or possible IFD. Four of the patients not treated with antifungals were diagnosed with a serious infection including 2 cases of Staphylococcus aureus bacteremia, and one case of disseminated Mycobacterium avium complex. CONCLUSION: We identified a high incidence of IFD among patients with HM related to a pathogenic sequence variant of GATA2. The wide range of variant allele frequency observed raises the possibility that either inherited or acquired GATA2 dysfunction could incur predisposition to infection. These data suggest that personalized genetic diagnostics of patients with HM may be useful for assessment of infectious risk. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810134/ http://dx.doi.org/10.1093/ofid/ofz360.2274 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Bold, Tyler D
Vedula, Rahul S
Cheng, Matthew P
Marty, Francisco M
Lindsley, R Coleman
2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
title 2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
title_full 2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
title_fullStr 2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
title_full_unstemmed 2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
title_short 2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
title_sort 2596. invasive fungal disease in patients with gata2 variant hematologic malignancy
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810134/
http://dx.doi.org/10.1093/ofid/ofz360.2274
work_keys_str_mv AT boldtylerd 2596invasivefungaldiseaseinpatientswithgata2varianthematologicmalignancy
AT vedularahuls 2596invasivefungaldiseaseinpatientswithgata2varianthematologicmalignancy
AT chengmatthewp 2596invasivefungaldiseaseinpatientswithgata2varianthematologicmalignancy
AT martyfranciscom 2596invasivefungaldiseaseinpatientswithgata2varianthematologicmalignancy
AT lindsleyrcoleman 2596invasivefungaldiseaseinpatientswithgata2varianthematologicmalignancy